Northstar Distribution Centre 8912 Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Northstar Distribution Centre 8912 Pharmaceutical Import Records from India — 4 Products, $2.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Northstar Distribution Centre 8912 — Pharmaceutical Importer Profile (2026) | 4 Products, $2.5M Trade | TransData Nexus

Northstar Distribution Centre 8912

Pharmaceutical Importer · United States · Advanced Antibiotics Focus · $2.5M Total Trade · DGFT Verified

Northstar Distribution Centre 8912 is a pharmaceutical importer based in United States with a total trade value of $2.5M across 4 products in 3 therapeutic categories. Based on 50 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Northstar Distribution Centre 8912 sources from 2 verified Indian suppliers, with Dr.reddy's Laboratories Limited accounting for 96.8% of imports.

Northstar Distribution Centre 8912 — Import Portfolio & Supplier Network

Northstar Distribution Centre 8912 import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Northstar Distribution Centre 8912?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr.reddy's Laboratories Limited	$1.5M	30	96.8%
Dr Reddy S Laboratories Limited	$50.0K	1	3.2%

Northstar Distribution Centre 8912 sources from across .

What Formulations Does Northstar Distribution Centre 8912 Import?

Formulation	Value	Ships
300038454 ciprofloxacin 0.3% and	$250.0K	5
300038454 ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle ns, batch-23020279 mfg-01.11.2023	$150.0K	3
300038454 ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle ns batch-23020281 mfg-01.12.2023	$150.0K	3
300038454 ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle ns batch-23020280 mfg-01.12.2023	$150.0K	3
Ertapenem for INJ. 1g/vial 10s ns (968	$50.0K	1
Ertapenem for INJ. 1g/vial 10s ns (971	$50.0K	1
300038454 ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle ns, batch-23020242 mfg-01.10.2023	$50.0K	1
Ertapenem for INJ. 1g/vial 10's ns (980x 10's packs = 9800 nos	$50.0K	1
Ertapenem for INJ. 1g/vial 10's ns (988x 10's packs = 9880 nos	$50.0K	1
Ertapenem for INJ. 1g/vial 10's ns (941x 10's packs = 9410 nos)	$50.0K	1
Ertapenem for INJ. 1g/vial 10's ns (991x 10's packs = 9910 nos)	$50.0K	1
Ertapenem for INJ. 1g/vial 10's ns (982x 10's packs = 9820 nos)	$50.0K	1
Ertapenem for INJ. 1g/vial 10's ns (964x 10's packs = 9640 nos)	$50.0K	1
300038454 ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle ns, batch-24020019 mfg-01.01.2024	$50.0K	1
Ertapenem for INJ. 1g/vial 10's ns (951x 10's packs = 9510 nos)	$50.0K	1

Northstar Distribution Centre 8912 imports 21 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ciprofloxacin	Antibiotics	$800.0K	16	0.3%	3
2	Ertapenem	Advanced Antibiotics	$700.0K	14	0.6%	10
3	Dexamethasone	Corticosteroids	$550.0K	11	0.3%	6
4	Ofloxacin	Advanced Antibiotics	$450.0K	9	0.2%	4

Northstar Distribution Centre 8912 imports 4 pharmaceutical products across 3 categories into United States totaling $2.5M.

Northstar Distribution Centre 8912 — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Northstar Distribution Centre 8912 is a pharmaceutical importer based in the United States, specializing in the procurement of finished pharmaceutical formulations from India. The company is headquartered at 4853 Crumpler Road, Memphis, Tennessee 38141. While specific information about its parent company is not publicly available, Northstar Distribution Centre 8912 plays a significant role in the U.S. pharmaceutical distribution network by sourcing a diverse range of medications from Indian manufacturers.

The company's import activities are substantial, with a total import value of $2.5 million USD across 50 shipments from India. These imports encompass four distinct products across three therapeutic categories, indicating a strategic approach to sourcing medications that address various medical needs. The top five imported products include Ciprofloxacin, Ertapenem, Dexamethasone, and Ofloxacin, collectively accounting for 100% of the company's pharmaceutical imports. This concentration suggests a focused product portfolio, potentially aimed at meeting specific market demands within the United States.

2Distribution Network

Northstar Distribution Centre 8912 operates a distribution center located at 4853 Crumpler Road, Memphis, Tennessee 38141. This strategic location positions the company to effectively serve various regions within the United States. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the Memphis facility's central location facilitates efficient distribution across the country. The company's geographic coverage likely extends nationwide, ensuring timely delivery of pharmaceutical products to meet the needs of healthcare providers and patients.

3Industry Role

In the U.S. pharmaceutical supply chain, Northstar Distribution Centre 8912 functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from Indian manufacturers, the company acts as an intermediary between foreign producers and the U.S. market. This role is crucial in ensuring the availability of a diverse range of medications, particularly generics, which are essential for providing cost-effective treatment options to patients. Through its import activities, Northstar Distribution Centre 8912 contributes to the overall efficiency and competitiveness of the U.S. pharmaceutical distribution network.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Northstar Distribution Centre 8912

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Northstar Distribution Centre 8912's sourcing strategy exhibits a high degree of concentration, with its top five imported products accounting for 100% of its pharmaceutical imports. This singular focus on a limited product range may indicate a strategic choice to specialize in specific therapeutic areas, potentially aligning with market demands or the company's expertise. However, such concentration also introduces risks associated with supply chain disruptions, regulatory changes, or shifts in market demand for these particular medications. The company's reliance on a narrow product portfolio necessitates robust risk management strategies to mitigate potential vulnerabilities.

2Supply Chain Resilience

The resilience of Northstar Distribution Centre 8912's supply chain is closely tied to its sourcing practices. With a portfolio concentrated on four products from two Indian suppliers—DR.REDDY'S LABORATORIES LIMITED and DR REDDY S LABORATORIES LIMITED—the company faces potential risks related to supplier dependency. The limited number of suppliers may expose the company to challenges such as production delays, quality control issues, or geopolitical factors affecting trade relations. To enhance supply chain resilience, it would be prudent for Northstar Distribution Centre 8912 to diversify its supplier base and establish contingency plans to address potential disruptions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal requirements for drug safety, efficacy, and quality. For Indian pharmaceutical products, the FDA requires that manufacturers comply with Good Manufacturing Practice (GMP) standards, which are internationally recognized and ensure that products are consistently produced and controlled according to quality standards. The FDA also mandates that all imported drugs be approved for safety and efficacy before they can be marketed in the U.S.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Importers must ensure that their products are manufactured in facilities that adhere to FDA-recognized GMP standards, such as those certified by the European Union (EU GMP), World Health Organization (WHO GMP), or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are essential for demonstrating compliance with quality standards. Additionally, importers must obtain wholesale distribution authorization, which involves registering with the FDA and providing detailed information about the products being imported. This process ensures that all pharmaceutical products entering the U.S. market meet the necessary safety and efficacy standards.

Northstar Distribution Centre 8912 — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Northstar Distribution Centre 8912's focus on importing advanced antibiotics, antibiotics, and corticosteroids aligns with the ongoing demand for these medications in the U.S. healthcare system. Advanced antibiotics are crucial for treating complex infections, while antibiotics remain a staple in combating bacterial diseases. Corticosteroids are widely used for their anti-inflammatory properties in various medical conditions. The company's strategic emphasis on these therapeutic areas suggests a commitment to addressing critical healthcare needs and providing essential treatments to patients.

2Sourcing Profile

Northstar Distribution Centre 8912's sourcing strategy is centered on generic pharmaceutical formulations, primarily from Indian manufacturers. This approach leverages India's reputation as a global supplier of affordable and high-quality generics, often referred to as the "pharmacy to the world." By focusing on finished pharmaceutical formulations, the company ensures that products are ready for immediate distribution, streamlining the supply chain and reducing time to market. This strategy allows Northstar Distribution Centre 8912 to offer cost-effective treatment options to the U.S. market while maintaining high standards of quality and compliance.

3Market Positioning

Seller's Guide — How to Become a Supplier to Northstar Distribution Centre 8912

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Northstar Distribution Centre 8912, particularly those offering high-quality generic formulations in the therapeutic areas of advanced antibiotics, antibiotics, and corticosteroids. The company's existing focus on these product categories indicates a sustained demand and a willingness to expand its supplier base to meet market needs. Potential suppliers should ensure compliance with FDA regulations, including GMP standards and labeling requirements, to establish a successful partnership. Diversifying the supplier base can also enhance supply chain resilience and mitigate risks associated with over-reliance on a limited number of suppliers.

2Requirements & Qualifications

Indian exporters seeking to supply Northstar Distribution Centre 8912 and the U.S. market must adhere to FDA regulations, including compliance with GMP standards recognized by the FDA. Manufacturing facilities should be registered with the FDA, and products must be approved for safety and efficacy. Labeling must meet

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Northstar Distribution Centre 8912

What products does Northstar Distribution Centre 8912 import from India?

Northstar Distribution Centre 8912 imports 4 pharmaceutical products across 3 categories. Top imports: Ciprofloxacin ($800.0K), Ertapenem ($700.0K), Dexamethasone ($550.0K), Ofloxacin ($450.0K).

Who supplies pharmaceuticals to Northstar Distribution Centre 8912 from India?

Northstar Distribution Centre 8912 sources from 2 verified Indian suppliers. The primary supplier is Dr.reddy's Laboratories Limited (96.8% of imports, $1.5M).

What is Northstar Distribution Centre 8912's total pharmaceutical import value?

Northstar Distribution Centre 8912's total pharmaceutical import value from India is $2.5M, based on 50 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Northstar Distribution Centre 8912 focus on?

Northstar Distribution Centre 8912 imports across 3 categories. The largest: Advanced Antibiotics (46.0%), Antibiotics (32.0%), Corticosteroids (22.0%).

Get Full Northstar Distribution Centre 8912 Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.